* Infinity Pharmaceuticals Inc INFI.OQ INFI.O is expected
to show a fall in quarterly revenue when it reports results on
July 28 (estimated).
* The Cambridge, Massachusetts-based company is expected to
report a 22.4% decrease in revenue to $279.33 thousand from
$360 thousand a year ago, according to the mean estimate from 6
analysts, based on Refinitiv data.
* Refinitiv's mean analyst estimate for Infinity
Pharmaceuticals Inc is for a loss of 14 cents per share. For the
same quarter last year, the company reported a loss of 16 cents
per share.
* The current average analyst rating on the shares is "buy" and
the breakdown of recommendations is 5 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in the
last three months.
* Wall Street's median 12-month price target for Infinity
Pharmaceuticals Inc is $8, about 71.3% above its last closing
price of $2.30.
* Previous quarterly performance (using preferred earnings
measure in US dollars).
QUARTER STARMINE REFINITIV ACTUAL BEAT, SURPRI
ENDING SMARTESTIM IBES MET, SE %
ATE® ESTIMATE MISSED
Mar. 31 2021 -0.12 -0.12 -0.15 Missed -20.2
Dec. 31 2020 -0.16 -0.16 -0.16 Met -2.1
Sep. 30 2020 -0.15 -0.16 -0.16 Met -2.6
Jun. 30 2020 -0.20 -0.19 -0.16 Beat 16.1
Mar. -0.12 -0.13 -0.19 Missed -43.7
31 2020
Dec. 31 2019 -0.19 -0.19 -0.20 Missed -4.7
Sep. 30 2019 -0.13 -0.10 -0.20 Missed -109.4
Jun. 30 2019 -0.15 -0.07 -0.18 Missed -173.8
This summary was machine generated July 26 at 11:26 GMT. All
figures in US dollars unless otherwise stated